New Jersey Trim Clinic

Tirzepatide vs Semaglutide: Comparing GLP-1 Medications

Published by New Jersey Trim Clinic · Updated 2025-01-20

Two Leading GLP-1 Medications

The landscape of medical weight loss has been transformed by two groundbreaking medications: semaglutide and tirzepatide. Both belong to the GLP-1 receptor agonist class, but they differ in important ways that may influence which one is the better fit for your weight loss goals. Understanding these differences can help you have an informed conversation with your medical provider.

Both medications are administered as once-weekly injections and have demonstrated substantial weight loss results in clinical trials. However, their mechanisms, efficacy profiles, and side effect experiences differ enough to warrant a detailed comparison.

How Each Medication Works

Semaglutide is a single-action GLP-1 receptor agonist. It mimics the GLP-1 hormone, which your body naturally produces after eating. By activating GLP-1 receptors in the brain and digestive system, semaglutide reduces appetite, slows gastric emptying, and helps regulate blood sugar levels. This results in reduced hunger, fewer cravings, and a quieter relationship with food.

Tirzepatide takes a dual-action approach. It activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism is sometimes referred to as a "twincretin" effect. The GIP component adds additional metabolic benefits, including enhanced insulin sensitivity and potentially greater effects on fat metabolism. This dual pathway may explain why tirzepatide has shown slightly greater weight loss in head-to-head comparisons.

Clinical Trial Results

In the STEP clinical trial program, semaglutide (at the 2.4 mg dose) produced an average weight loss of approximately 15–17% of body weight over 68 weeks. These results were considered groundbreaking when they were first published and established semaglutide as a leading weight loss medication.

Tirzepatide's SURMOUNT clinical trial program showed even more impressive results. At the highest dose (15 mg), participants lost an average of 22.5% of their body weight over 72 weeks. Some participants lost more than 25% of their starting weight. These results represent some of the largest weight reductions ever achieved with a non-surgical intervention.

It is important to note that clinical trial results represent averages across large populations. Individual results will vary based on factors including starting weight, adherence to the medication schedule, lifestyle modifications, and individual metabolic responses.

Side Effects Comparison

Both medications share similar potential side effects, which are primarily gastrointestinal in nature. The most commonly reported include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These effects tend to be most pronounced during the dose-escalation phase and typically diminish over time.

In clinical trials, tirzepatide showed slightly higher rates of gastrointestinal side effects at the highest doses compared to semaglutide. However, the gradual dose-escalation protocols used for both medications help minimize these effects. Most patients find that side effects are manageable and temporary.

Both medications carry warnings about potential risks including pancreatitis, gallbladder problems, and thyroid tumors (observed in animal studies). Neither medication should be used by individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Cost and Accessibility

Pricing for both medications can vary significantly depending on the source and whether you are using insurance coverage. Brand-name versions of both medications (Wegovy for semaglutide, Zepbound for tirzepatide) can be expensive without insurance.

New Jersey Trim Clinic offers affordable access to these medications through compounded formulations with all-inclusive pricing. Our programs are designed to remove financial barriers so that effective medical weight loss is accessible to patients across New Jersey and the tri-state area.

Which One Is Right for You?

The choice between semaglutide and tirzepatide depends on several factors unique to your situation. Your medical history, current health conditions, weight loss goals, and budget all play a role. Some patients respond better to one medication than the other, and your physician can help guide this decision based on your individual needs.

During your free consultation with New Jersey Trim Clinic, a board-certified physician will review your health profile and discuss which medication may be the best starting point. Some patients begin with semaglutide and transition to tirzepatide if they need additional support, while others start with tirzepatide based on their clinical profile.

The Importance of Medical Supervision

Regardless of which medication you choose, medical supervision is essential. Both semaglutide and tirzepatide are prescription medications that require ongoing monitoring by a qualified healthcare provider. Your physician will track your weight loss progress, monitor for side effects, adjust dosing as needed, and ensure that the treatment remains safe and effective throughout your journey.

Our telehealth model makes this supervision convenient and accessible. You can check in with your medical team from anywhere in New Jersey without taking time off work or sitting in a waiting room.

MEDICAL SOURCES & FURTHER READING

Read the source alongside the specific topic it supports. These independent sources do not endorse New Jersey Trim Clinic. Research findings are not a prediction of your results.

  • NIH/NIDDK — Prescription Medications to Treat Overweight & Obesity

    Supports: Weight-management medication requires individualized prescribing; eligibility, benefits, risks and ongoing treatment should be discussed with a healthcare professional. Nutrition and physical activity remain part of treatment.

  • Mayo Clinic — Prescription weight-loss drugs

    Supports: Prescription weight-loss medicines have eligibility restrictions, potential side effects and a need for professional oversight; they are used alongside lifestyle measures.

  • Cleveland Clinic — GLP-1 Agonists

    Supports: GLP-1 receptor agonists act on appetite and satiety, help regulate blood glucose and can slow stomach emptying. Common adverse effects include nausea, vomiting and diarrhea.

    Evidence limits: The extent and duration of effects differ by drug, dose and individual; a general mechanism does not establish a guaranteed response.

  • Once-Weekly Semaglutide in Adults with Overweight or Obesity

    Supports: Semaglutide 2.4 mg plus lifestyle intervention produced weight loss in the STEP 1 randomized trial; gastrointestinal adverse events were reported.

    Evidence limits: The main trial reported mean weight change of −14.9% at 68 weeks. This is not a predicted clinic outcome or proof that every semaglutide formulation has the same results.

  • FDA — Wegovy (semaglutide) prescribing information

    Supports: The approved product's label describes contraindications including personal or family history of medullary thyroid carcinoma and MEN 2, dose escalation, pregnancy considerations, gastrointestinal reactions, and warnings including pancreatitis, gallbladder disease and kidney injury due to volume depletion.

    Evidence limits: This label is for Wegovy, not approval of New Jersey Trim Clinic or a compounded formulation. Individual prescribing decisions require a licensed provider.

  • Tirzepatide Once Weekly for the Treatment of Obesity

    Supports: The SURMOUNT-1 trial studied tirzepatide at different doses in adults with obesity or overweight without diabetes and reported weight reduction and gastrointestinal adverse events.

    Evidence limits: SURMOUNT-1 was placebo-controlled, not a head-to-head comparison with semaglutide. Results do not establish guaranteed outcomes or equivalence of compounded medicines.

  • Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

    Supports: SURMOUNT-5 directly compared maximum tolerated doses of tirzepatide and semaglutide in adults with obesity without diabetes and reported greater average weight reduction with tirzepatide at 72 weeks.

    Evidence limits: This was an open-label trial in a defined population. The finding does not determine which treatment is appropriate for an individual, establish clinic outcomes, or validate compounded formulations.

  • The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity

    Supports: A randomized study reported reduced hunger, food cravings and energy intake, and improved control of eating with semaglutide.

    Evidence limits: This study does not establish a diagnosis of 'food noise', prove that all intrusive food thoughts have one cause, or show that every patient will experience relief. It found no evidence of delayed gastric emptying at week 20 using its indirect test.

  • NIH/NIDDK — Factors Affecting Weight & Health

    Supports: Weight is influenced by lifestyle, sleep, medicines, health conditions, family history and other factors; insufficient sleep can affect hunger.

    Evidence limits: This general guidance does not establish the cause of an individual patient's cravings, emotional eating, insulin resistance or weight changes.

  • FDA — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

    Supports: Compounded GLP-1 drugs are not FDA-approved. FDA describes dosing, quality, storage and other safety concerns, and advises that compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug.

    Evidence limits: Pharmacy registration is not FDA approval of a compounded product. Clinical trials of approved drugs do not establish the safety or effectiveness of compounded formulations.

  • FDA — Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks

    Supports: FDA identifies potential safety risks and limited human safety information for certain substances proposed for compounding, including some peptides.

    Evidence limits: This safety source does not substantiate claims that unapproved peptide treatments improve cognition, muscle, tissue repair, recovery or longevity.

RESEARCH & REFERENCES

General education is not individualized medical advice. Prescription treatment requires evaluation by a licensed provider. Eligibility, medication and dosing depend on individual circumstances.

Compounded drugs are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before marketing. Compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug. Published studies of approved medications do not establish equivalent safety or effectiveness of compounded products.

Browse more New Jersey Trim Clinic patient education.